Original articleSynthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase
Introduction
Melanomas are malignant skin cancers and their incidence has been constantly increasing during the last decades affecting about 150,000 new patients per year in the world [1]. They are fast growing, multiresistance tumors with a high capacity for metastasis, which characterizes them as very aggressive cancers. Although early diagnosis and surgical resection of melanomas enable the cure in a high percentage of cases, melanoma metastasis still presents a very poor prognosis mainly because of its resistance to chemotherapic agents [2], [3]. Due to the low availability of chemotherapeutic agents to treat melanoma, dacarbazine, which has been used for 30 years now, remains the standard drug even with a response rate averaging only 15–20% [4]. Until recently, the treatment of patients with advanced melanoma was unsuccessful. However, the situation has begun to change in the last years. The careful molecular characterization of tumors has been extremely important in the discovery of new drugs against melanoma [5], [6]. On the other hand, this strategy is much unpredictable and expensive, and it is not always possible to find new effective and selective promising molecules [7]. This scenario encourages the development of more efficient and cheaper approaches in the search for new compounds for the treatment of cancer.
Presently, the synthetic alkyl-lysophospholipid analogs (ALPs) constitute a novel class of compounds, namely antineoplastic phospholipids (APs), with promising anticancer activity. This class includes clinically relevant drugs such as edelfosine, miltefosine and perifosine [8]. The most important characteristic of the action mechanism of APs is that they do not target DNA. They easily insert into the lipid bilayer, which might interfere with lipid metabolism and signal transduction, inducing apoptosis [9].
With the recent advent of APs to the treatment of malignant tumors, we investigated whether the central precursor in the biosynthesis of phospholipids has antitumor effects. The primary amine phosphoethanolamine (PEA), a lipid involved in phospholipid turnover, is a substrate for many phospholipids of the cell membranes, especially phosphatidylcholine [10]. We previously reported that the synthetic phosphoethanolamine (Pho-s) is highly cytotoxic to a wide variety of tumor cells, including the human melanomas SK-MEL-28 and MEWO and the murine melanoma B16-F10, by inducing apoptosis [11].
The aims of the present study are to investigate the mechanisms of Pho-s mediated mitochondria-dependent apoptosis in tumor cells. In the present study, we provide experimental evidence to support the hypothesis that Pho-s has high antitumor activity against melanoma.
Section snippets
Chemicals and antibody
Synthetic Pho-s was synthesized and supplied in the Laboratory of Chemistry and Polymers Technology, University of Sao Paulo, Sao Carlos, Brazil. B16-F10 cells (number CRL-6475) were purchased from the American Type Culture Collection (ATCC, Baltimore, MD, USA). The antibody against Caspase-3 was obtained from Biotium Inc. (Hayward, CA, USA). Propidium iodide (PI), JC-1 (5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide), Methylthiazolyldiphenyl-tetrazolium bromide and
Phosphoethanolamine inhibits cell proliferation of B16-F10 cells
In previous report, we demonstrated cytotoxic effect of Pho-s on melanoma cells. In this work, we started by verifying the antiproliferative effects of Pho-s on B16-F10 cells at lower concentrations, after 96 h of treatment. We observed that Pho-s inhibits cell proliferation of B16-F10 cells in vitro in a dose-response manner. Moreover, we showed that it does not induce changes in the cell morphology (Fig. 1A). The reduction in cell proliferation by Pho-s was significant (***P < 0.001) at
Discussion
Metastatic melanomas are the most therapeutically challenging malignancies. Its disappointing treatment results evidence the urge for the development of better strategies and new compounds [12], [13]. In this regard, APs have pharmacological properties involving the inhibition of multiple pathways, leading to apoptosis, making these compounds attractive candidates for malignant tumor therapy [14], [15], [16].
In the present study, we investigated the antiproliferative and antitumor effects of
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
Acknowledgements
This work was supported by a Sao Paulo Research Foundation – (FAPESP) grant (2007/50571-3; Doctorate and Master Fellowship 2008/56089-1; 2010/50220-9).
References (21)
- et al.
Melanoma: new insights and new therapies
J Invest Dermatol
(2012) - et al.
Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease
Brain Res
(1987) - et al.
Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis
J Biol Chem
(2002) - et al.
Mitochondrial permeability transition in Ca(2 + )-dependent apoptosis and necrosis
Cell Calcium
(2011) - et al.
Promising pre-clinical validation of targeted radionuclide therapy using a [131i] labelled iodoquinoxaline derivative for an effective melanoma treatment
J Cancer Sci Ther
(2009) - et al.
Inhibition of melanoma growth and metastasis by ATF2-derived peptides
Cancer Res
(2004) - et al.
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53
PLoS One
(2011) - et al.
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy
Mol Cancer Ther
(2003) - et al.
Clin drug development: portals of discovery
Cancer Res
(2012) - et al.
Advanced malignant melanoma: immunologic and multimodal therapeutic strategies
J Oncol
(2010)
Cited by (20)
Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model
2018, Biomedicine and PharmacotherapyCitation Excerpt :The precise mechanism by which some inhibitors could contrarily act is unknown, but provides a warning note for targeting anticancer drug discovery. In previous studies developed by our group, Pho-s showed in vivo anti-melanoma properties [3] and anti-metastatic effect in a renal carcinoma model6. In this model, Pho-s inhibited lung metastasis in nude mice and blocked endothelial cells proliferation, migration and tube formation, besides provoked cell cycle arrest at the G2/M phase.
Enhancement of gama-aminobutyric acid (GABA) and other health-related metabolites in germinated red rice (Oryza sativa L.) by ultrasonication
2018, Ultrasonics SonochemistryCitation Excerpt :The Phe content of the ultrasound-treated GRR (Group B) increased by 44.20% compared to the control (Group A) (Table 1). O-phosphoethanolamine, an ethanolamine derivative and a subunit of cell membrane phospholipids metabolism [37], was also significantly increased in the ultrasound-treated samples (Table 1, Table 2, Fig. S2). Phosphoethanolamine can be further converted into phosphatidylethanolamines (PE).
Synthetic phosphoethanolamine induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells through the mitochondrial pathway
2013, Biomedicine and PharmacotherapyCitation Excerpt :The primary amine phosphoethanolamine (PEA), a lipid involved in phospholipid turnover, is a substrate for many phospholipids of the cell membranes, especially phosphatidylcholine [9]. It has been shown that synthetic phospohoethanolamine (Pho-s), a central precursor in the biosynthesis of phospholipids, reduces the expression of pro-apoptotic Bad/Bax in B16-F10 melanoma cells it leads to increased caspase-3 activity, triggers apoptosis and blocks the cell cycle in either the S or the G2/M phase, depending on the concentration of the drug [10]. More importantly, treatment of B16-F10 melanoma-bearing mice with Pho-s resulted in inhibition of tumor growth, increased survival and reduction of metastasis.
Prognostic relationship of metabolic profile obtained of melanoma B16F10
2013, Biomedicine and PharmacotherapyCitation Excerpt :In addition, we found an increased of cells with DNA fragmented. Our preview studies have demonstrated the increase of cells at the G2/M in Earlich ascites tumor and melanoma B16B10 [12,13]. The fact that tumors depend on the metabolic pathways of glycolysis or gluconeogenesis to meet their metabolic demands have been recognized since the early 20th century, known as the Warburg effect.
Local tumour response to neoadjuvant therapy with 2-aminoethyl dihydrogen phosphate in dogs with soft tissue sarcoma
2022, Veterinary Medicine and Science